Literature DB >> 7529673

Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.

A J Czaja1, S Magrin, C Fabiano, G Fiorentino, O Diquattro, A Craxi, L Pagliaro.   

Abstract

To determine if hepatitis C virus infection influences the behavior of type 1 autoimmune hepatitis and to assess the performance parameters of third-generation immunoassays for viral infection in this disease, 64 patients with different patterns of disease behavior were assessed retrospectively for antibodies to hepatitis C virus by third-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay and for HCV RNA by polymerase chain reaction. Hepatitis C virus RNA was detected in seven patients (11%) and antibodies to hepatitis C virus were found in five (8%). All patients who had an acute onset of illness or who sustained remission after therapy lacked HCV RNA in serum. In contrast, four of 31 patients who relapsed (13%) and three of 17 patients who failed treatment (18%) had HCV RNA in serum. Patients with HCV RNA were indistinguishable from those without HCV RNA; in three patients, infection was recognized only by testing for HCV RNA. Four of seven patients with HCV RNA responded fully to corticosteroids, although each relapsed after drug withdrawal. Smooth muscle antibodies (43% versus 91%, P = 0.006) and concurrent smooth muscle and antinuclear antibodies (0% versus 60%, P = 0.003) occurred less frequently in patients with HCV RNA than in counterparts without HCV RNA. The specificity of the third-generation enzyme immunoassay was 98% and its overall predictability was 94%. Its sensitivity, however, was 57% and false positive results occurred in 20%. Hepatitis C virus infection is an uncommon determinant of disease behavior in type 1 autoimmune hepatitis, but it may be present in relapse or treatment failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529673     DOI: 10.1007/bf02063938

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  44 in total

1.  Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis.

Authors:  A J Czaja; H F Taswell; J Rakela; C M Schimek
Journal:  Mayo Clin Proc       Date:  1991-06       Impact factor: 7.616

2.  Hepatitis C virus infection in patients with nonalcoholic chronic liver disease.

Authors:  J M Sánchez-Tapias; J M Barrera; J Costa; M G Ercilla; A Parés; L Comalrrena; F Soley; J Bruix; X Calvet; M P Gil
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

3.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

4.  Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis.

Authors:  A J Czaja; G L Davis; J Ludwig; H F Taswell
Journal:  Hepatology       Date:  1984 Jul-Aug       Impact factor: 17.425

5.  Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis.

Authors:  G L Davis; A J Czaja; A H Baggenstoss; H F Taswell
Journal:  Mayo Clin Proc       Date:  1982-05       Impact factor: 7.616

6.  Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II, and III.

Authors:  L S Mitchel; L J Jeffers; K R Reddy; H Cheinquer; E Coelho-Little; R Moreda; T Parker; M Silva; X M Li; M de Medina
Journal:  Am J Gastroenterol       Date:  1993-07       Impact factor: 10.864

7.  Absence of hepatitis C virus in British patients with type 1 autoimmune chronic active hepatitis--a polymerase chain reaction and serological study.

Authors:  E Silva; R Sallie; C Tibbs; I McFarlane; P Johnson; R Williams
Journal:  J Hepatol       Date:  1993-09       Impact factor: 25.083

8.  Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.

Authors:  A J Czaja; M P Manns; H A Homburger
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

9.  Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis.

Authors:  A J Czaja; J Ludwig; A H Baggenstoss; A Wolf
Journal:  N Engl J Med       Date:  1981-01-01       Impact factor: 91.245

10.  Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis.

Authors:  A J Czaja; H F Taswell; J Rakela; D Rabe
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

View more
  13 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 3.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

Review 4.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

5.  Hepatocellular carcinoma in autoimmune hepatitis.

Authors:  S Z Park; D M Nagorney; A J Czaja
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 6.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 7.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 8.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

9.  Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

10.  Validation of scoring system for diagnosis of autoimmune hepatitis.

Authors:  A Czaja; H A Carpenter
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.